Blackstone Inc. logo

Blackstone Inc. (BX)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
126. 91
-2.06
-1.5973%
$
149.63B Market Cap
- P/E Ratio
0.59% Div Yield
4.8M Volume
- Eps
$ 128.97
Previous Close
Add Transaction
Day Range
126.12 131
Year Range
101.73 190.09
Want to track BX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Sunstone to Sell Hyatt Regency San Francisco Hotel to Blackstone Fund

Sunstone to Sell Hyatt Regency San Francisco Hotel to Blackstone Fund

SHO is set to sell the Hyatt Regency San Francisco to a Blackstone fund for $279M as it redeploys proceeds through share buybacks and weighs further uses.

Zacks | 3 weeks ago
Blackstone says withdrawal limits are a ‘feature and not a flaw' designed to ‘protect investors from themselves'

Blackstone says withdrawal limits are a ‘feature and not a flaw' designed to ‘protect investors from themselves'

Dan Oneglia, liquid-credit strategist, called the capping mechanism a “feature and not a flaw” of the structure.

Marketwatch | 3 weeks ago
Blackstone plans $30 billion investment in Japan AI data centres, Nikkei reports

Blackstone plans $30 billion investment in Japan AI data centres, Nikkei reports

Blackstone is planning ​to invest $30 ‌billion in Japan's ​artificial intelligence ​data centers over ⁠the ​next three ​to five years, its president ​and ​chief operating officer Jonathan ‌Gray ⁠told Nikkei in a ​recent ​interview, ⁠the business daily ​reported ​on ⁠Tuesday.

Reuters | 3 weeks ago
Undercovered Dozen: Dynex Capital, Blackstone, Rithm Capital, And More

Undercovered Dozen: Dynex Capital, Blackstone, Rithm Capital, And More

The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between June 5 and June 11. This curated selection aims to provide fresh investment ideas and foster community discussion around under-the-radar equities. Readers are encouraged to engage, share perspectives, and highlight additional overlooked investment opportunities.

Seekingalpha | 1 month ago
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding

Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding

Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company's IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotechnology equity research analyst Salveen Richter.

Marketbeat | 1 month ago
Blackstone: The Market Is Selling Over A Problem That Doesn't Exist

Blackstone: The Market Is Selling Over A Problem That Doesn't Exist

Blackstone Inc. (BX) is rated a Buy, offering quality growth at discounted valuations despite sector-wide private credit concerns. BX's diversified model, robust credit underwriting, and focus on investment-grade secured debt position it to absorb private credit shocks better than peers. Key growth catalysts in AI/data center infrastructure, 401(k) regulatory changes, and perpetual capital, are not fully priced into BX shares.

Seekingalpha | 1 month ago
Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript

Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript

Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript

Seekingalpha | 1 month ago
Blackstone: One Of The Best Opportunities Of The Decade

Blackstone: One Of The Best Opportunities Of The Decade

BX's stock price has recently dropped by nearly 40%. And it left investors wondering whether it's time to sell or buy even more. BX's fundamentals don't justify the sell-off, as its inflows, fee growth, AUM, and other key metrics were either record-level or very strong. The market is wrong about BX being a victim of AI. In fact, it's one of the beneficiaries.

Seekingalpha | 1 month ago
Blackstone restricts flagship fund withdrawals as private asset fears reemerge

Blackstone restricts flagship fund withdrawals as private asset fears reemerge

Blackstone restricts flagship fund withdrawals as private asset fears reemerge

Cnbc | 1 month ago
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.

Marketbeat | 1 month ago
Blackstone Raises $13.1 Billion in Its Largest Asia Private-Equity Fund

Blackstone Raises $13.1 Billion in Its Largest Asia Private-Equity Fund

The New York-based alternative asset manager raised more than the $10 billion target for the Blackstone Capital Partners Asia III fund.

Wsj | 1 month ago
Apollo, Blackstone work on $36 billion debt deal for Anthropic, Bloomberg News reports

Apollo, Blackstone work on $36 billion debt deal for Anthropic, Bloomberg News reports

Apollo Global Management and Blackstone are working to ​bring in additional investors for ‌about $36 billion debt financing tied to AI startup Anthropic PBC's efforts to ​expand its AI infrastructure, Bloomberg ​News reported on Thursday.

Reuters | 1 month ago
Loading...
Load More